| Date | Title | Description |
| 26.05.2025 | HealthCap V distributes its holding in BONESUPPORT to its limited partners and general partner | HealthCap V distributes its holding in BONESUPPORT to its limited partners and general partner
Mon, May 26, 2025 18:00 CET Report this content
HealthCap V LP, part of the HealthCap group of venture capital funds investing globally in life s... |
| 25.05.2023 | Strong long-term results with CERAMENT®G for severe open fractures – study from Manchester University Hospital | Published: 2023-05-25
BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announces the recent publication of long-term follow-up data demonstrating sustained high limb salvage rates and low deep i... |
| 11.05.2023 | 100% limb salvage rate in complex diabetic foot cases with CERAMENT® G/V – study from King’s College Hospital, London | Published: 2023-05-10
BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announces the recent publication of clinical data demonstrating 100% limb salvage rate and 100% ulcer resolution with the c... |
| 27.04.2023 | BONESUPPORT HOLDING AB (publ) – Publishes Q1 2023 interim report | Published: 2023-04-27
BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the first quarter 2023.
CONTINUED STRONG GROWTH
JANUARY – MARCH 2023
“S... |
| 16.02.2023 | BONESUPPORT HOLDING AB (publ) – publishes year-end report 2022 | BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the fourth quarter 2022 and the full year 2022.
68 PERCENT SALES GROWTH IN THE QUARTER
OCTOBER –... |
| 28.10.2022 | BONESUPPORT HOLDING AB (publ) – Publishes Q3 2022 interim report | Published: 2022-10-27
BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the third quarter 2022.
ACCELERATED SALES GROWTH
JULY – SEPTEMBER 2022
... |
| 26.10.2022 | BONESUPPORT’s CERAMENT®G used in first U.S. patient cases | BONESUPPORT, an emerging leader in orthobiologics for the management of bone injuries, today announces that the company’s antibiotic-eluting bone graft CERAMENT G (Gentamicin) has been used surgically for the first time in patients in the U... |
| 11.10.2022 | BONESUPPORT’s FDA Authorized CERAMENT® G to be featured at Orthopedic Trauma Association Annual Meeting (OTA) | During the conference, BONESUPPORT is sharing insights from a new study on the long-term effectiveness of its CERAMENT® G technology, the first and only injectable combination antibiotic bone graft substitute that recently received market a... |
| 18.08.2022 | New Study Shows BONESUPPORT’s CERAMENT G Technology Delivers 94% Limb Salvage Rate for Patients with Diabetic Foot Infections | The clinical study published by Vasukutty et al. is powerful validation of our groundbreaking technology for the management of diabetic bone infection, especially in a challenging cohort of patients.
BOSTON (PRWEB) August 18, 2022
BONESUPPO... |
| 19.05.2022 | U.S. FDA grants market authorization for BONESUPPORT’s CERAMENT G (Gentamicin) | This is a significant recognition for the power and promise of our technology, as we are the first-to-market in the U.S. with this breakthrough combination device/drug bone graft.
BOSTON (PRWEB) May 19, 2022
BONESUPPORT ™, an emerging leade... |
| 22.03.2022 | CORRECTION: BONESUPPORT’s Technology to be Featured in Clinical Program at American Academy of Orthopaedic Surgeons Meeting in Chicago | BOSTON (PRWEB) March 22, 2022
Today, BONESUPPORT, innovator of injectable bone grafts that change the standard of care for patients with bone infections, is announcing plans to exhibit at The American Academy of Orthopaedic Surgeons Meeting... |
| 21.03.2022 | BONESUPPORT’s Technology to be Featured in Clinical Program at American Academy of Orthopaedic Surgeons Meeting in Chicago | BOSTON (PRWEB) March 21, 2022
Today, BONESUPPORT, innovator of injectable bone grafts that change the standard of care for patients with bone infections, is announcing plans to exhibit at The American Academy of Orthopaedic Surgeons Meeting... |
| 28.02.2022 | Delays within FDA postpones CERAMENT G De Novo decision | Delays within FDA postpones CERAMENT G De Novo decision
Mon, Feb 28, 2022 08:00 CET Report this content
Lund, Sweden, 08:00 CET, February 28, 2022 –BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, toda... |
| 17.02.2022 | BONESUPPORT Holding AB (publ) – Publishes full year report 2021 | BONESUPPORT Holding AB (publ) – Publishes full year report 2021
Thu, Feb 17, 2022 08:00 CET Report this content
Lund, Sweden, 08:00 CET, February 17, 2022 – BONESUPPORT Holding AB (publ), an emerging leader in orthobiologics for the managem... |
| 10.02.2022 | BONESUPPORT HOLDING AB (publ) – Invitation to conference call and webcast for year end report 2021 | BONESUPPORT HOLDING AB (publ) – Invitation to conference call and webcast for year end report 2021
Thu, Feb 10, 2022 10:00 CET Report this content
Lund, Sverige, 10.00 CET, 10 February 2022 – BONESUPPORT HOLDING AB (publ), an emerging leade... |
| 01.02.2022 | Change in number of shares and votes in BONESUPPORT Holding AB (publ) | Change in number of shares and votes in BONESUPPORT Holding AB (publ)
Tue, Feb 01, 2022 09:00 CET Report this content
Lund, Sweden, 09:00 CET, 1 February 2022 – BONESUPPORT Holding AB (publ), an emerging leader in orthobiologics for the man... |
| 13.01.2022 | BONESUPPORT signs distribution agreement with OrthoPediatrics | BONESUPPORT signs distribution agreement with OrthoPediatrics Thu, Jan 13, 2022 15:30 CET
Lund, Sweden, 15:30 CET, 22-01-13 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced that the c... |
| 30.12.2021 | Change in number of shares and votes in BONESUPPORT Holding AB (publ) | Change in number of shares and votes in BONESUPPORT Holding AB (publ) Thu, Dec 30, 2021 12:00 CET
Lund, Sweden, 12:00 CET, 30 December 2021 – BONESUPPORT Holding AB (publ), an emerging leader in orthobiologics for the management of bone inj... |
| 30.11.2021 | Change in number of shares and votes in BONESUPPORT Holding AB (publ) | Change in number of shares and votes in BONESUPPORT Holding AB (publ) Tue, Nov 30, 2021 12:00 CET
Lund, Sweden, 12:00 CET, 30 November 2021 – BONESUPPORT Holding AB (publ), an emerging leader in orthobiologics for the management of bone inj... |
| 04.11.2021 | BONESUPPORT Holding AB (publ) – Publishes Q3 2021 Interim report | BONESUPPORT Holding AB (publ) – Publishes Q3 2021 Interim report Thu, Nov 04, 2021 08:00 CET
Lund, Sweden, 08:00 CEST, November 4, 2021 – BONESUPPORT Holding AB (publ), an emerging leader in orthobiologics for the management of bone injurie... |
| 28.10.2021 | BONESUPPORT HOLDING AB (publ) – Interim Report Q3 2021 Invitation to conference call and webcast | BONESUPPORT HOLDING AB (publ) – Interim Report Q3 2021 Invitation to conference call and webcast Thu, Oct 28, 2021 10:00 CET
Lund, Sverige, 10.00 CET, 28 October 2021 – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for... |
| 11.10.2021 | BONESUPPORT appoints Michael Wrang Mortensen to EVP R&D and Operations | BONESUPPORT appoints Michael Wrang Mortensen to EVP R&D and Operations Mon, Oct 11, 2021 11:00 CET
Lund, Sweden, 11:00 CET, 211011 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, announced today... |
| 30.09.2021 | Change in number of shares and votes in BONESUPPORT Holding AB (publ) | Change in number of shares and votes in BONESUPPORT Holding AB (publ) Thu, Sep 30, 2021 12:00 CET
Lund, Sweden, 12:00 CET, 30 September 2021 – BONESUPPORT Holding AB (publ), an emerging leader in orthobiologics for the management of bone in... |
| 28.09.2021 | BONESUPPORT – SUPPLEMENTARY US DENOVO APPLICATION SUBMITTED | BONESUPPORT – SUPPLEMENTARY US DENOVO APPLICATION SUBMITTED Tue, Sep 28, 2021 08:00 CET
Lund, Sweden, 08:00 CET, 28-09-21 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced that the com... |
| 09.09.2021 | Study results on FORTIFY are inconclusive | Study results on FORTIFY are inconclusive Thu, Sep 09, 2021 19:40 CET
Lund, Sweden, 19:40 CET, 09 09 21 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced inconclusive results for the c... |
| 31.08.2021 | Change in number of shares and votes in BONESUPPORT Holding AB (publ) | Change in number of shares and votes in BONESUPPORT Holding AB (publ) Tue, Aug 31, 2021 18:00 CET
Lund, Sweden, 18:00 CET, 31 August 2021 – BONESUPPORT Holding AB (publ), an emerging leader in orthobiologics for the management of bone injur... |
| 15.07.2021 | BONESUPPORT Holding AB (publ) – Publishes Q2 2021 Interim report | BONESUPPORT Holding AB (publ) – Publishes Q2 2021 Interim report Thu, Jul 15, 2021 08:00 CET
Lund, Sweden, 08:00 CEST, July 15, 2021 – BONESUPPORT Holding AB (publ), an emerging leader in orthobiologics for the management of bone injuries, ... |
| 17.06.2021 | BONESUPPORT HOLDING AB (PUBL)
BONESUPPORT : receives “breakthrough device designation” for CERAMENT G for the indication trauma | Lund, Sweden, 10:00 CET, 17 06 21 BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced that the company's antibiotic eluting product CERAMENT G has been categorized as a breakthrough device... |
| 20.05.2021 | BULLETIN FROM THE ANNUAL SHAREHOLDERS’ MEETING IN BONESUPPORT HOLDING AB ON 20 MAY 2021 | BULLETIN FROM THE ANNUAL SHAREHOLDERS’ MEETING IN BONESUPPORT HOLDING AB ON 20 MAY 2021 Thu, May 20, 2021 14:00 CET
Lund, Sweden, 14:00 CET, 20 May 2021 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injurie... |
| 21.06.2017 | BONESUPPORT IPO: Trading of shares commences today on Nasdaq Stockholm |
Today June 21, trading of BONESUPPORT™’s shares commences on Nasdaq Stockholm, and the offering has been set at SEK 29 per share. The offering attracted strong interest among Swedish and international investors.
The final price of the of... |
| 12.06.2017 | BONESUPPORT™ announces initial public offering on Nasdaq Stockholm | BONESUPPORT announces its initial public offering on Nasdaq Stockholm’s main market. The objective is to broaden the shareholder base through a new share issue of SEK 500 million with the subsequent fundraising to be used to further support... |
| 27.10.2016 | BONESUPPORT raises $37 million to deliver further value from CERAMENT platform | BONESUPPORT raises $37 million (SEK 327 million) in a financing round led by Tellacq AB, with participation from current major shareholders, including Industrifonden, HealthCap, Lundbeckfond Ventures, AP3 (The Third Swedish National Pension... |
| 27.10.2016 | Bonesupport Raises $37m in Financing | Bonesupport AB, a Lund, Sweden-based developer of innovative injectable bioceramic bone scaffolds to treat bone voids caused by trauma, infection, disease or related surgery, raised $37m (SEK327m) in a combination of equity and debt financi... |
| 27.10.2016 | Term Sheet — Thursday, October 27 | ALL DEAL EVERYTHING
Some very brief notes today, as I spent a chunk of the morning on Twitter’s unusually early earnings call. In case you’ve been following the reported sale talks on that turnaround story, CEO Jack Dorsey kicked off the sa... |
| 15.04.2015 | Bonesupport Closes $14M Funding | Bonesupport, a Lund, Sweden-based provider of injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, closed a $14m round of funding.
The round was led by a new investmen... |
| 19.02.2013 | Bonesupport lands CE Mark for next-gen antibiotic bone graft substitute | Swedish orthopedic trauma products maker Bonesupport won CE Mark approval in the European Union for its next-generation Cerament|G injectable antibiotic-eluting bone substitute.
The Cerament|G product is an osteoconductive, ceramic substanc... |
| 19.06.2012 | BONESUPPORT Raises SEK70M in Funding | BONESUPPORT, a Lund, Sweden-based developer of injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, has received SEK70m (approximately $9.9m/€8m) in the second and fin... |
| 23.06.2011 | BONESUPPORT Raises SEK120M | BONESUPPORT, a Lund, Sweden-based medical technology company that specializes in the development of high-tech solutions for the treatment of vertebral compression fractures and other osteoporotic fractures, has raised SEK120m (approximately... |
| - | BONESUPPORT™ Announces CERAMENT™ Focused Research Collaboration with Rigshospitalet, Copenhagen University Hospital | Rigshospitalet to evaluate CERAMENT™ platform for use in bone tumors
LUND, Sweden, Jan. 7, 2016 /PRNewswire/ — BONESUPPORT™, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentati... |
| - | BONESUPPORT’S FDA NOTIFICATION: APPROVAL ON DENOVO PATHWAY FOR CERAMENT G WILL REQUIRE ADDITIONAL DATA AND CLARIFICATIONS | Lund, Sweden, 14:30 CET, 27 02 21 –BONESUPPORT ™, a leading company active in orthobiology for the treatment of skeletal injuries, today announced that the company has received a notification from the US Food and Drug Administration (FDA) t... |
| - | Emil Billbäck appointed CEO of BONESUPPORT | Lund, Sweden 08.30 CET, 23 January 2018 – BONESUPPORT (Nasdaq Stockholm: BONEX), an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery ba... |
| - | BONESUPPORT HOLDING AB (publ) – Interim Report – January – September 2017 | Lund, Sweden, 08.00 CET, 2 November 2017 – BONESUPPORT™, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAME... |
| - | BONESUPPORT HOLDING AB (publ) – Interim Report Q2 2021 Invitation to conference call and webcast | Lund, Sverige, 10.00 CET, 8 July 2021 – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone injuries, will publish its Interim Report Q2 2021, on the 15 July at 08.00 am CET.
The Company will hold... |
| - | BONESUPPORT Holding AB (publ) – Publishes Q3 2021 Interim report | Lund, Sweden, 08:00 CEST, November 4, 2021 – BONESUPPORT Holding AB (publ), an emerging leader in orthobiologics for the management of bone injuries, today publishes the interim report for the third quarter 2021.
BEST SALES QUARTER TO DATE... |
| - | BONESUPPORT™ Announces Appointment Of Life Sciences Industry Veteran, Richard Davies, As New Chief Executive Officer | Mr. Davies Brings over 25 Years of Life Sciences Industry Experience to BONESUPPORT™
Current Chief Executive Officer, Lloyd Diamond, to Transition to Role of Chief Business Officer
Lund, Sweden, (PRNEWSWIRE) January 22, 2016 – BONESUPPORT... |
| - | BONESUPPORT FORTIFY PATIENT ENROLLEMENT FINALIZED EARLIER THAN ORIGINAL PLAN | Lund, Sweden, 16.30 CET, 15 June 2020 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced that the enrollment of the FORTIFY study on CERAMENT® G has been completed with 198 subjects enr... |
| - | BONESUPPORT Holding AB (publ) – Publishes Q1 2022 interim report | Published: 2022-05-04
BONESUPPORT Holding AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the first quarter 2022.
STRONG SALES GROWTH
JANUARY – MARCH 2022
“U.S. ... |
| - | BONESUPPORT achieves private coverage in South Africa | Published: 2022-06-16
BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announces that South Africa’s largest private insurance funder, Discovery Health and the key hospital groups, Life Healthca... |
| - | Bulletin from the annual shareholders’ meeting in BONESUPPORT HOLDING AB on 19 May 2020 | Lund, Sweden, 12.00 CET, 19 May 2020 – BONESUPPORT HOLDING AB, an emerging leader in orthobiologics for the management of bone injuries, today announces that the annual shareholders’ meeting was held in the company on this day and that all ... |
| - | BONESUPPORT™ Announces Nature Publication Of Pre-Clinical Study Highlighting CERAMENT™’s Attractive Bone Remodeling Properties and as a Local Drug Delivery Platform for Bone Disease | Lund, Sweden, 1 June 2016 – BONESUPPORT AB, an emerging leader in innovative injectable bioresorbable bone graft substitute products to treat bone voids caused by trauma, infection, disease or related surgery today announced the publication... |
| - | BONESUPPORT HOLDING AB (publ) – Interim Report Q3 2020 – invitation to conference call and webcast | Lund, Sweden, 10.00 am CET, 28 October 2020 – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone injuries, will publish its Interim Report Q3 2020, on 5 November at 08.00 am CET.
The Company will... |
| - | BONESUPPORT – SUPPLEMENTARY US DENOVO APPLICATION SUBMITTED | Lund, Sweden, 08:00 CET, 28-09-21 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced that the company has submitted a supplementary De Novo application to the US Food and Drug Administr... |
| - | Bonesupport appoints Jerry Chang as Executive Vice President of Research & Development | Lund, Sweden, 12.00 CEST, 19 September 2017 – BONESUPPORTTM, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CE... |
| - | BONESUPPORT HOLDING AB (publ) – Invitation to conference call and webcast for Interim Report Q2 2022 | BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, will publish its Interim Report Q2 2022, on the 14 July 2022 at 08.00 am CEST.
The Company will hold a conference call and an online pr... |
| - | BONESUPPORT HOLDING AB (publ) – Interim Report | January – June 2018
Lund, Sweden, 08.00 CET, 26 July 2018 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids, today announces the publication of its Q2 and Half-year Interim Report.
FINANCIAL HIGHLIGHTS
... |
| - | BONESUPPORT HOLDING AB – Full Year Report 2020 – invitation to conference call and webcast | Lund, Sweden, 10.00 am CET, 10 February 2021 – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone injuries, will publish its Full Year Report 2020, on 17 February 2021 at 08.00 am CET.
The Compan... |
| - | Change in number of shares and votes in BONESUPPORT HOLDING AB (publ) | Lund, Sweden, 12:00 pm CET, 31 March 2021 – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone injuries, today announced a change in the number of shares and votes. During March, the number of sha... |
| - | BONESUPPORT awarded Synthetic Implantable Products agreement with Premier | —– This press release has been modified to comply with the Premier IR guidelines —–
Lund, Sweden, 13.00 CET, 20 April 2021 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, has been awarded a group p... |
| - | BONESUPPORT™ Receives FDA Approval to Initiate IDE Clinical Study | FORTIFY Study to Assess CERAMENT G as part of Surgical Repair of Open Diaphyseal Tibial Fractures
Lund, Sweden, 9 August – BONESUPPORT AB, an emerging leader in innovative injectable bioceramic bone substitute products to treat bone voids ... |
| - | TWELVE-MONTH FOLLOW-UP OF CERAMENT™ WITH GENTAMICIN CONFIRMS SIGNIFICANT AND SUSTAINED ERADICATION OF CHRONIC INFECTION AND DEMONSTRATED FORMATION OF NEW BONE | New data presented at the 33rd Annual Meeting of The European Bone & Joint Infection Society (EBJIS)
Lund, Sweden, (PRNEWSWIRE) September 24, 2014 – BONESUPPORT,an emerging leader in injectable bone substitutes for orthopedic trauma, b... |
| - | BONESUPPORT HOLDING AB presents health economic evidence | Lund, Sweden, 19.00 CET, 18 September 2019 – BONESUPPORT HOLDING AB, listed on Nasdaq Stockholm – an emerging leader in orthobiologics for the management of bone voids announced today that health economic data was presented during the EBJIS... |
| - | BONESUPPORT HOLDING AB (PUBL) – PUBLISHES Q2 2021 INTERIM REPORT | Lund, Sweden, 08:00 CEST, July 15, 2021 – BONESUPPORT Holding AB (publ), an emerging leader in orthobiologics for the management of bone injuries, today publishes the interim report for the second quarter 2021.
58% SALES GROWTH IN CONSTANT... |
| - | Updated CERAMENT BONE VOID FILLER (BVF) instructions for use for the US market | Lund, Sweden, 15:00 CET, 19 October 2020 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, announces that the company, through a 510 (k) to the Food and Drug Administration (FDA), has updated its CERA... |
| - | BONESUPPORT HOLDING AB (publ) – Publishes Full year report 2020 | Lund, Sweden, 08:00 am CET, 17 February 2021 – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone injuries, today publishes the interim report for the fourth quarter and the full year 2020.
STR... |
| - | Change in the management team | Lund, Sweden, 17:00 PM CET, 12 February 2020 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries announces a change in its management team. Patrick O’Donnell will leave BONESUPPORT and his role as Genera... |
| - | BONESUPPORT HOLDING AB (publ) – Interim Report Q1 2020 – invitation to conference call and webcast | Lund, Sweden, 08.00 am CET, 29 April 2020 – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone injuries, will publish its Interim Report Q1 2020, on 8 May at 08.00 am CET.
The Company will hold a... |
| - | BONESUPPORT™ ANNOUNCES AVAILABILITY IN EUROPE OF CERAMENT™|G IN 5 mL VOLUME TO ADDRESS GROWING MARKET DEMAND | CERAMENT™|G 5 mL to be utilized for infection management and prophylaxis in diabetic foot procedures and small extremities
Lund, Sweden, (PRNEWSWIRE) March 1, 2016 – BONESUPPORT™, an emerging leader in injectable bone substitutes for ortho... |
| - | Strong CERAMENT data published in Science Advances | Lund, Sweden, 15.00 CET, Nov 30, 2020 BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced that new preclinical data has been published in one of the highest ranked research journals, Scien... |
| - | BONESUPPORT™ ANNOUNCES RESULTS OF CERAMENT™|BONE VOID FILLER PROSPECTIVE PILOT STUDY DEMONSTRATING COMPLETE BONE REMODELING IN BENIGN BONE TUMORS | • 93% of patients had full or partial cyst resolution at 12 months
• No post-operative infections reported during follow-up period
• No fractures reported during the follow-up period
Lund, Sweden, (PRNEWSWIRE) December 10, 2015 – BONESUP... |
| - | BONESUPPORT HOLDING AB (publ) – Publishes Q2 2020 Interim report | Lund, Sweden, 08:00 am CET, July 17, 2020 – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone injuries, today publishes the interim report for the second quarter 2020.
STRONG SALES GROWTH IN THE... |
| - | BONESUPPORT HOLDING AB signs an agreement on a working capital facility of SEK 60 million | Lund, Sweden, 12:00 pm CET, 31 January 2020 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced that the company has signed an agreement with Skandinaviska Enskilda Banken (SEB) for a cr... |
| - | BONESUPPORT HOLDING AB (publ) – Full Year Report 2019 – invitation to conference call and webcast | Lund, Sweden, 08.00 am CET, 19 February 2020 – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone injuries, will publish its Full Year Report 2019, on the 26 February at 08.00 am CET.
The Company... |
| - | BONESUPPORT appoints Michael Roth as General Manager & Executive Vice President Commercial Operations North America | Lund, Sweden, 17.00 CET, 29 April 2020 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries announces a change in its leadership team that will take place June 1, 2020. Michael Roth starts in the position... |
| - | BONESUPPORT Holding AB publishes Annual Report 2020 | Lund, Sweden, 16:00 CET, 13 April 2021 – BONESUPPORT Holding AB (publ), an emerging leader in orthobiologics for the management of bone injuries, announces that the Annual Report for 2020 is now available as a pdf on the group’s web page, w... |
| - | BONESUPPORT HOLDING AB (publ) – Invitation to conference call and webcast for Interim Report Q1 2022 | Published: 2022-04-27
BONESUPPORT Holding AB (publ), a leading company in orthobiologics for the management of bone injuries, will publish its Interim Report Q1 2022, on the 4 May 2022 at 08.00 am CEST.
The Company will hold a conference ... |
| - | BONESUPPORT receives approval to market CERAMENT™ in India CERAMENT™IG is the first injectable antibiotic eluting bone substitute in India | Lund, Sweden, (PRNEWSWIRE) February 25, 2015 – BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced that it has received r... |
| - | Delays within FDA postpones CERAMENT G De Novo decision | Lund, Sweden, 08:00 CET, February 28, 2022 –BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced that due to internal delays at the U.S. Food and Drug Administration (FDA), the agency has i... |
| - | BONESUPPORT receives “breakthrough device designation” for CERAMENT G for the indication trauma | Lund, Sweden, 10:00 CET, 17 06 21 BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced that the company’s antibiotic eluting product CERAMENT G has been categorized as a breakthrough device... |
| - | BONESUPPORT CLOSES $14 MILLION IN FUNDING LED BY MAJOR SCANDINAVIAN PENSION FUND | Financing will be used to grow CERAMENT™ platform and expand market penetration
Lund, Sweden, (PRNEWSWIRE) April 15, 2015 – BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrumen... |
| - | BONESUPPORT HOLDING AB (publ) – Interim Report Q2 2020 – invitation to conference call and webcast | Lund, Sweden, 08.00 am CET, 9 July 2020 – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone injuries, will publish its Interim Report Q2 2020, on 17 July at 08.00 am CET.
The Company will hold a... |
| - | BONESUPPORT starts its own sales organization in the Netherlands | Lund, Sweden, 15.00 CET, 8 June 2020 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announces that the company is from 1 July 2020 starting direct sales within the Netherlands.
“We have a pr... |
| - | BONESUPPORT appoints Fergus MacLeod as General Manager and Executive Vice President Commercial Operations EUROW | Lund, Sweden, 16:00 CET, November 12 2019BONESUPPORT™ an emerging leader in orthobiologics for the management of bone injuries, announces changes in its leadership team that will take place November 18, 2019.
Fergus MacLeod starts in the p... |
| - | The Orthopaedic Revolution | Osteomyelitis, or Bone Infection is a $1.7 billion market where prolonged, long-term antibiotic therapy, multiple surgical interventions and the threat of amputation are the current standard of care. Rising prosthetic infections, diabetic u... |
| - | BONESUPPORT HOLDING AB (publ) – Publishes Q3 2019 Interim report | Lund, Sweden, 7 November 2019 08.00 am CET, – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone voids, today publishes the interim report for the third quarter 2019.
BONESUPPORT’S BEST QUARTER E... |
| - | BONESUPPORT™ Announces First Patient Enrolled in FORTIFY Trial with CERAMENT®|G, a novel injectable, antibiotic-eluting bone graft substitute | Lund, Sweden, 22 May 2017– BONESUPPORT AB, an emerging leader in innovative injectable bioceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery, today announced that the first patient h... |
| - | BONESUPPORT signs distribution agreement with OrthoPediatrics | Lund, Sweden, 15:30 CET, 22-01-13 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced that the company has entered into a distribution agreement with OrthoPediatrics Corp., a leader in t... |
| - | BONESUPPORT HOLDING AB (publ) – Q3 2019 Interim Report – invitation to conference call and webcast | Lund, Sweden, 08.00 am CET, 30 October 2019 – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone voids, will publish its Q3 2019 interim report on the 7 November 2019 at 08.00 am CET.
The Company... |
| - | BONESUPPORTTM CERTiFy STUDY ON CERAMENT® BONE VOID FILLER NOW PUBLISHED IN THE JOURNAL OF BONE AND JOINT SURGERY | Lund, Sweden, 08:45 CET, December 9 2019 BONESUPPORTTM, an emerging leader in orthobiologics for the management of bone injuries, today announced the publication of the Level I clinical study CERTiFy in the highly ranked Journal of Bone and... |
| - | Study results on FORTIFY are inconclusive | Lund, Sweden, 19:40 CET, 09 09 21 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced inconclusive results for the company’s Investigational Device Exemption (IDE) study; FORTIFY. The pr... |
| - | Single stage surgical procedure achieves 96% infection eradication rate | Lund, Sweden, 1 September 2016 – BONESUPPORT AB, an emerging leader in innovative injectable bioresorbable bone graft substitute products to treat bone voids caused by trauma, infection, disease or related surgery, today announced the publi... |
| - | BONESUPPORT HOLDING AB (PUBL) – PUBLISHES FULL YEAR REPORT 2021 | Lund, Sweden, 08:00 CET, February 17, 2022 – BONESUPPORT Holding AB (publ), an emerging leader in orthobiologics for the management of bone injuries, today publishes the interim report for the fourth quarter 2021 and the full year 2021.
ST... |
| - | BONESUPPORT receives market authorization for CERAMENT G in the US | Published: 2022-05-18
BONESUPPORT ™, an emerging leader in orthobiologics for the management of bone injuries, today announced that the company has received market authorization from the US Food and Drug Administration (FDA), for the compa... |
| - | BONESUPPORT moves to Mid Cap | Lund, Sweden, 11.00 CET, Dec 17, 2020 BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, will be moved to the Mid Cap segment on Nasdaq Stockholm from 4 January 2021.
Based on Nasdaq Nordic’s recent ann... |
| - | BONESUPPORT HOLDING AB (publ) – Interim Report Q1 2021 Invitation to conference call and webcast | Lund, Sverige, 10.00 CET, 29 April 2021 – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone injuries, will publish its Interim Report Q1 2021, on the 6 May at 08.00 am CET.
The Company will hold... |
| - | BONESUPPORT HOLDING AB (publ) – Interim Report Q3 2021 Invitation to conference call and webcast | Lund, Sverige, 10.00 CET, 28 October 2021 – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone injuries, will publish its Interim Report Q3 2021, on the 4 November at 08.00 am CET.
The Company wi... |
| - | Change in number of shares and votes in BONESUPPORT HOLDING AB (publ) | Lund, Sweden, 16:00 CET, 31 August 2020 – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone injuries, today announced a change in the number of shares and votes. During August, the number of shar... |
| - | BONESUPPORT™ Announces 20,000 Patients Now Treated With CERAMENT™ | LUND, Sweden, Jan. 11, 2016 /PRNewswire/ — BONESUPPORT™, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced today the Company has rea... |
| - | BONESUPPORT™ Announces Positive Data Highlighting The Use Of CERAMENT™|G In The Management Of Osteomyelitis In The Infected Diabetic Foot | LUND, Sweden, Jan. 5, 2016 /PRNewswire/ — BONESUPPORT™, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced data from two studie... |
